Evelo Biosciences
Total Raised
$132.5MInvestors Count
6Deal Terms
3Funding, Valuation & Revenue
5 Fundings
Evelo Biosciences has raised $132.5M over 5 rounds.
Evelo Biosciences's latest funding round was a IPO for $84.96M on May 9, 2018.
Evelo Biosciences's latest post-money valuation is from May 2018.
Sign up for a free demo to see Evelo Biosciences's valuations in May 2018 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/9/2018 | IPO | $84.96M | 1 | |||
2/20/2018 | Series C | |||||
1/18/2017 | Series B | |||||
11/4/2015 | Series A | |||||
Other Investors |
Date | 5/9/2018 | 2/20/2018 | 1/18/2017 | 11/4/2015 | |
|---|---|---|---|---|---|
Round | IPO | Series C | Series B | Series A | Other Investors |
Amount | $84.96M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
Evelo Biosciences Deal Terms
3 Deal Terms
Evelo Biosciences's deal structure is available for 3 funding rounds, including their IPO from May 09, 2018.
Round | IPO | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series B | |||||||||||||||
Series A |
Evelo Biosciences Investors
6 Investors
Evelo Biosciences has 6 investors. Flagship Pioneering invested in Evelo Biosciences's Series B funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
11/4/2015 | 1/18/2017 | 2 Series A, Series B (2017) | Venture Capital | Massachusetts | ||
Corporate Venture | California | |||||
Corporation | New Jersey | |||||
Corporate Venture | Minnesota | |||||
Corporate Venture | California |
First funding | 11/4/2015 | ||||
|---|---|---|---|---|---|
Last Funding | 1/18/2017 | ||||
Investor | |||||
Rounds | 2 Series A, Series B (2017) | ||||
Board Seats | |||||
Type | Venture Capital | Corporate Venture | Corporation | Corporate Venture | Corporate Venture |
Location | Massachusetts | California | New Jersey | Minnesota | California |
Evelo Biosciences Acquisitions
1 Acquisition
Evelo Biosciences acquired 1 company. Their latest acquisition was Epiva Biosciences on July 12, 2016.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
7/12/2016 | Other Venture Capital | Merger | 2 |
Date | 7/12/2016 |
|---|---|
Investment Stage | Other Venture Capital |
Companies | |
Valuation | |
Total Funding | |
Note | Merger |
Sources | 2 |
Compare Evelo Biosciences to Competitors
Vedanta Biosciences develops Live Biotherapeutic Products (LBPs) for treating gastrointestinal diseases in the biopharmaceutical industry. The company provides therapies that use defined consortia of bacteria to modulate the human microbiome and host immune system, focusing on inflammatory bowel disease and recurrent Clostridium difficile infection. Vedanta's products aim to address gut dysbiosis and related diseases. It was founded in 2010 and is based in Cambridge, Massachusetts.
LISCure Biosciences is a clinical-stage pharmaceutical company specializing in microorganism-based medicines within the healthcare sector. The company focuses on injectable bacteria-mediated cancer immunotherapy and oral microbiome therapeutics. LISCure's products aim to develop therapeutics for oncology, metabolic diseases, autoimmune diseases, and central nervous system disorders. It was founded in 2018 and is based in Gyeonggi-do, South Korea.
Seres Therapeutics is a commercial-stage company focused on developing microbiome therapeutics within the healthcare sector. The company offers live biotherapeutic products aimed at preventing bacterial bloodstream and antimicrobial resistant infections, as well as treating gastrointestinal-related immune diseases. Seres Therapeutics was formerly known as Seres Health, Inc.. It was founded in 2010 and is based in Cambridge, Massachusetts.
Loading...